As far as long term investment. Pulled from their 10Q
For the six months ended December 31, 2011, approximately 80% of total net sales were derived from one customer and as compared to approximately 88% of total net sales were derived from two customers in the six months ended December 31, 2010. The loss of this customer would have an adverse affect on our operations.
Not what you want to see....
I have been holding for a couple of months. Got in at $8.49. Seems to be growing and doing well. Presenting at a Growth Stock meeting. I do see growth. Maybe $12-$13 in the short term.
Looks like there were some others that were cancelled too.
Time (ET) After Hours
Price After Hours
Share Volume 16:07 $ .0275 20,389,000 15:45 $ .032 200,000 - Cancelled Trade 15:45 $ .032 200,000 - Cancelled Trade 15:45 $ .032 200,000 - Cancelled Trade
Read more: http://www.nasdaq.com/symbol/neom/after-hours#ixzz1qXY6QRgl
Building his empire.
March 28, 2012
INDIANAPOLIS, Ind. and LOS ANGELES, Cal. - Strand Diagnostics, LLC, maker of the "know error" system, and NantWorks, LLC announced that they have entered into an agreement whereby Strand will receive up to $30 million in funding from NantWorks, LLC over the next 3 years. The money will be used to accelerate the company’s growth, scale its operations infrastructure, and expand sales and marketing efforts.
“This investment is a very important next step for the growth of our business,” said Strand Diagnostics President, Ken Cerney. “NantWorks and Dr. Soon-Shiong provide additional resources, experience, and relationships that will help to grow our platform more quickly.”
“The era of quantitative genomic medicine is upon us. Clinical decision support utilizing gene and bioinformatics will transform healthcare as we know it today. The Know Error founding team has laid the groundwork for an innovative system that improves patient safety and diagnostic accuracy,” said NantWorks Chairman and CEO, Dr. Patrick Soon-Shiong. “Their products fit directly into our vision of quantitative medicine and next-generation personalized medicine.”
Entire Article here: